CervoMed Stock (NASDAQ:CRVO)


ForecastRevenueOwnershipFinancialsChart

Previous Close

$8.84

52W Range

$1.80 - $25.92

50D Avg

$5.40

200D Avg

$9.98

Market Cap

$73.71M

Avg Vol (3M)

$4.65M

Beta

0.19

Div Yield

-

CRVO Company Profile


CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

15

IPO Date

May 23, 2008

Website

CRVO Performance


CRVO Financial Summary


Dec 24Dec 23Dec 22
Revenue-$7.14M-
Operating Income$-18.23M$-7.81M$-3.48M
Net Income$-16.29M$-2.17M$-5.80M
EBITDA$-18.23M$-2.17M-
Basic EPS$-2.02$-0.82$-11.20
Diluted EPS$-2.02$-0.82$-11.20

Fiscal year ends in Dec 24 | Currency in USD